Glaxo Wellcome has confirmed the line-up for its new marketing team, which will report to executive director, commercial development James Cochrane.
The pharmaceuticals giant, which announced last week that it intends to axe 7,500 staff following its merger last March, has appointed seven directors responsible for marketing across different disease types.
Three other directors will cover the licensing, business analysis and over-the-counter (otc) operations.
Mark Weedon, previously with Wellcome, is general manager otc operations. Tony Scullion is vice president, global licensing and alliances; Rita Sully is director, business analysis; and Brian Lovatt director, business economics.
Marketing for gastro-intestinal diseases will be overseen by Stuart Collinson; respiratory diseases by Darrell Baker; infectious diseases/antibacterial and influenza by Simon Cartmell; herpes by Bill Collier; central nervous system diseases by Ward Swift; infectious diseases/HIV, hepatitis by Peter Young; and new diseases by Derek Winstanley.
David O’Sullivan, marketing director of the group’s marketing company Warner Wellcome, says that the proposed staff cuts will not affect his operation.